FDA warns of rare eye condition causing blindness from GLP-1 weight loss medications

10 novembre 2026 | Maya Yang
The federal agency is requiring all GLP-1s to include information about the potential risk on warning labels The US Food and Drug Administration (FDA) has issued a new warning on GLP-1 medications – which can facilitate weight loss – over a rare eye condition that could lead to sudden and (…)
 Site référencé:  The Guardian